IDEAYA Biosciences, Inc. (IDYA)
38.85
+0.44
(+1.15%)
USD |
NASDAQ |
Sep 21, 16:00
38.85
0.00 (0.00%)
After-Hours: 20:00
IDEAYA Biosciences Free Cash Flow (Quarterly) : -89.08M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -89.08M |
| March 31, 2026 | -76.14M |
| December 31, 2025 | -90.83M |
| September 30, 2025 | 142.17M |
| June 30, 2025 | -63.14M |
| March 31, 2025 | -61.67M |
| December 31, 2024 | -122.76M |
| September 30, 2024 | -49.69M |
| June 30, 2024 | -33.86M |
| March 31, 2024 | -45.14M |
| December 31, 2023 | -24.59M |
| September 30, 2023 | -30.78M |
| June 30, 2023 | -34.34M |
| March 31, 2023 | -27.88M |
| December 31, 2022 | -23.37M |
| September 30, 2022 | -25.27M |
| June 30, 2022 | -21.93M |
| Date | Value |
|---|---|
| March 31, 2022 | -20.05M |
| December 31, 2021 | -17.26M |
| September 30, 2021 | -12.93M |
| June 30, 2021 | -13.51M |
| March 31, 2021 | -14.73M |
| December 31, 2020 | -11.78M |
| September 30, 2020 | 89.96M |
| June 30, 2020 | -13.68M |
| March 31, 2020 | -9.545M |
| December 31, 2019 | -8.922M |
| September 30, 2019 | -10.63M |
| June 30, 2019 | -10.72M |
| March 31, 2019 | -10.39M |
| December 31, 2018 | -7.785M |
| September 30, 2018 | -9.692M |
| June 30, 2018 | -6.108M |
| March 31, 2018 | -5.743M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Xencor, Inc. | -56.20M |
| UroGen Pharma Ltd. | -35.08M |
| MeiraGTx Holdings Plc | -38.87M |
| ACADIA Pharmaceuticals, Inc. | 95.69M |
| Alnylam Pharmaceuticals, Inc. | 292.04M |